Citations

Clear

4 citation(s) found for "Soriano, Alex".

Efficacy and Safety of Remdesivir in People With Impaired Kidney Function Hospitalized for COVID-19 Pneumonia: A Randomized Clinical Trial
Sise, Meghan E. , Santos, José Ramón, Goldman, Jason D. , Tuttle, Katherine R, Teixeira, J. Pedro , Seibert, A. F., Koullias, Yiannis , Llewellyn, Joe , Zhao, Yang , Hyland, Robert H. , Osinusi, Anu, Winter, Helen , Humeniuk, Rita , Hulter, Henry N., Gottlieb, Robert , Fusco, Dahlene N. , Birne, Rita , Small, Catherine B. , Plate, Markus, McPhail, Mark , Investigators, for the REDPINE, Ballesteros, Rosa , Malheiro, Luís , Silva, Gil, Correia, João Paulo , Vida, Ana Carlota, Silva, André, Carujo, Antonio, Fernandez, Jordi Carratala, Cruzado, Josep M. , Sandoval, Diego , Gimeno, Fransesc Puchades, Gómez‐Muñoz, Neus, Roma, María Martínez, Gallego, Juan Horcajada, Pablo, Castañeda, Silvia, Padilla Urrea, Sergio, Rial Crestelo, David, Santos Fernandez, Jose, Ramon, Benet, Susanna, Benítez, Rosa, Bracke, Carmen, Chamorro, Anna, Graterol, Fredzzia, Lladós, Gemma , Mateu, Lourdes , Rebollo, Boris, Romero, Alba , Soldevila, Laura , Abad, Elena, José, Alba San, Viladomiu, Alex Soriano, Abolnik, Igor Z., Acharya, Anjali , Allen, Leland, Bellovich, Keith, Burton, Mary Jane , Cameron, Miriam L., Criner, Gerard J., Criner, Lii-Yoong H, Lambert, Joseph, Rashid, Marium, Shore-Brown, Heidi, Diaz, George A., Dougherty, David W. , Erdmann, Nathaniel, Berrington, William R., Logar, Christine M., Vadivel, Nidyanandh, Everett, Allison, Lourdes, Gonzalez Suarez Maria, Berhe, Mezgebe , Colbert, Gates B. , Hebert, Christopher, Mehta, Ankit , Spak, Cedric W. , Estrada, Lorie, Vargas, Richard, Pham, Alex, Mason, Lynn, Tallmadge, Catherine, Braddom, Ariana, Nicholas, Melissa, Jamil, Aayla K. , McAllister, Ashley , Guerra, Christina, Sam, Teena , Solis, Edilia, Goyal, Munish, Laurence, Brett, Malhotra, Vinay , Manrique, Luis, McKinnell, James A., McMahon, Blaithin A. , Campbell, Ruth , Morse, Caryn G. , Navarro, Jesús, Ostrosky, Luis, Patel, Bela , Grimes, Carolyn Z. , Hernández, María , Mammadova, Mehriban, Nielsen, Laura, Umana, Virginia, Pusch, Tobias, Schrager, Harry, Mallada, Jason, Siegel, Marc , Slim, Jihad , Apodaca, Krystle D., Harkins, Michelle , Cunningham, Amy, Tuttle, Katherine R, Criner, Gerard J. , Tuttle, Katherine R. , Tuttle, Katherine R , Gottlieb, Robert L , Criner, Gerard , Teixeira, J Pedro , Tuttle, Katherine R, Regan, S. P. , Huang, Hailin , Stancampiano, Fernando F. , Libertin, Claudia R. , Investigators, for the REDPINE, Belhassen‐García, Moncef , Abelenda-Alonso, Gabriela , Rombauts, Alexander , Deltoro, Miguel García , España, Sergio, López, C. , Paredes, Roger , Viladomiu, Alex Soriano, Medjeral‐Thomas, Nicholas , Lobo, Suzana Margareth , Allen, Leland, Lambert, Joseph, Dougherty, David, Hebert, Christopher, Choe, Jennifer, McAllister, Ashley, Gotur, Deepa Bangalore , Koraishy, Farrukh M. , Malhotra, Vinay, Robinson, Philip Alan , Sanyal, Arun J. , Sriram, Peruvemba , Cunningham, Amy G, Tuttle, Katherine R

Mayo Clinic

Clinical Infectious Diseases | June 24, 2024 | Volume: 79 | Issue: 5 | Pages: 1172-1181

10.1093/cid/ciae333 | PMID 38913574 Get It

Abstract Background Few antiviral therapies have been studied in patients with coronavirus disease 2019 (COVID-19) and kidney impairment. Herein, the efficacy, safety, and pharmacokinetics of remdesivir, its metabolites, and sulfobutylether-β-cyclodextrin excipient were evaluated in hospitalized patients with COVID-19 and severe kidney impairment. Methods In REDPINE, a phase 3, randomized, double-blind, placebo-controlled study, participants aged ≥12 years hospitalized for COVID-19 pneumonia with acute kidney injury, chronic kidney disease, or kidney failure were randomized 2:1 to receive intravenous remdesivir (200 mg on day 1; 100 mg daily up to day 5) or placebo (enrollment from March 2021 to March 2022). The primary efficacy end point was the composite of the all-cause mortality rate or invasive mechanical ventilation rate through day 29. Safety was evaluated through day 60. Results Although enrollment concluded early, 243 participants were enrolled and treated (remdesivir, n = 163; placebo, n = 80). At baseline, 90 participants (37.0%) had acute kidney injury (remdesivir, n = 60; placebo, n = 30), 64 (26.3%) had chronic kidney disease (remdesivir, n = 44; placebo, n = 20), and 89 (36.6%) had kidney failure (remdesivir, n = 59; placebo, n = 30); and 31 (12.8%) were vaccinated against COVID-19. Composite all-cause mortality or invasive mechanical ventilation rates through day 29 were 29.4% and 32.5% in the remdesivir and placebo group, respectively (P = .61). Treatment-emergent adverse events were reported in 80.4% for remdesivir versus 77.5% for placebo, and serious adverse events in 50.3% versus 50.0%, respectively. Pharmacokinetic plasma exposure to remdesivir was not affected by kidney function. Conclusions Although the study was underpowered, no significant difference in efficacy was observed between treatment groups. REDPINE demonstrated that remdesivir is safe in patients with COVID-19 and severe kidney impairment. Clinical Trials Registration EudraCT 2020-005416-22; Clinical Trials.gov NCT04745351.
Role of Routine Suppressive Antibiotic Therapy After Debridement, Antibiotics, and Implant Retention for Acute Periprosthetic Joint Infections
Tai, Don Bambino Geno , Tande, Aaron J. , Langworthy, Benjamin , Abdel, Matthew P. , Berbari, Elie F. , Jutte, Paul C. , Soriano, Àlex , Suh, Gina A. , Wouthuyzen‐Bakker, Marjan , Jutte, Paul , Soriano, Alex , Suh, Gina A , Wouthuyzen-Bakker, Marjan , Tande, Aaron , Abdel, Matthew P , Tai, Don Bambino Geno , Have, Bas ten, Zijlstra, Wierd Pieter

Mayo Clinic

Open Forum Infectious Diseases | April 17, 2024 | Volume: 11 | Issue: 5 | Pages: No page available

10.1093/ofid/ofae216 | PMID 38778861 Get It

Abstract Background The first-line management strategy for acute periprosthetic joint infections (PJIs) is debridement, antibiotics, and implant retention (DAIR). Suppressive antibiotic therapy (SAT) after DAIR is proposed to improve outcomes, yet its efficacy remains under scrutiny. Methods We conducted a multicenter retrospective study in patients with acute PJI of the hip or knee who were treated with DAIR in centers from Europe and the United States. We analyzed the effect of SAT using a Cox model landmarked at 12 weeks. The primary covariate of interest was SAT, which was analyzed as a time-varying covariate. Patients who experienced treatment failure or were lost to follow-up within 12 weeks were excluded from the analysis. Results The study included 510 patients with 66 treatment failures with a median follow-up of 801 days. We did not find a statistically significant association between SAT and treatment failure (hazard ratio, 1.37; 95% CI, .79–2.39; P = .27). Subgroup analyses for joint, country cohort, and type of infection (early or late acute) did not show benefit for SAT. Secondary analysis of country cohorts showed a trend toward benefit for the US cohort (hazard ratio, 0.36; 95% CI, .11–1.15; P = .09), which also had the highest risk of treatment failure. Conclusions The utility of routine SAT as a strategy for enhancing DAIR's success in acute PJI remains uncertain. Our results suggest that SAT's benefits might be restricted to specific groups of patients, underscoring the need for randomized controlled trials. Identifying patients most likely to benefit from SAT should be a priority in future studies.
DAIR TO STOP: SUPPRESSIVE ANTIBIOTIC TREATMENT AFTER 12 WEEKS OF THERAPY IS NOT BENEFICIAL FOR ACUTE PERIPROSTHETIC JOINT INFECTIONS
Tai, Geno, Tande, Aaron J. , Langworthy, Benjamin , Have, Bas Ten, Jutte, Paul C. , Zijlstra, Wierd Pieter , Soriano, Àlex , Wouthuyzen‐Bakker, Marjan

Mayo Clinic

Orthopaedic Proceedings | November 24, 2023 | Volume: 105-B | Issue: SUPP_17 | Pages: 82-82

10.1302/1358-992x.2023.17.082 Get It

AimDebridement, antibiotics, and implant retention (DAIR) is a viable treatment option for acute periprosthetic joint infections (PJI). The landmark DATIPO trial of Bernard et al. concluded that six weeks is not non-inferior to 12-week antibiotic therapy for DAIR. However, it is unknown if suppressive antibiotic treatment (SAT) would improve patient outcomes. Therefore, our study aims to evaluate the utility of SAT after 12 weeks of therapy.MethodWe performed a retrospective study of patients with acute hip or knee PJI managed with DAIR at five institutions; in the U.S. (n=1), Netherlands (n=3), and Spain (n=1) from 2005–2020. We analyzed the effect of SAT using a Cox model among patients after 12 weeks of antibiotic treatment. The primary covariate of interest was whether the patient was on antibiotics after week 12, which was coded as a time-varying covariate. We decided a-priori to control for the clinically important risk factors such as age, sex, type of infection, modular exchange, joint, and presence of bacteremia and Staphylococcus aureus. We excluded patients who died, had treatment failure, or were lost to follow-up before 12 weeks. We defined treatment failure as infection recurrence (same or different organism), unexpected reoperation, or death due to infection.ResultsThere were 504 patients included in the study. The majority were female (58%, n=292), with a mean age of 70 years ago (SD 11). Hips and knees were equally proportioned. Primary arthroplasties represented 69% of the total cohort (n=349). Treatment failure was 11.9% in the total cohort (n=60). There was no statistically significant association between SAT after 12 weeks and treatment failure (HR 1.25, p=0.45, 95% CI 0.70–2.24). This finding was consistent across different subgroups, including hip or knee joints, early or late acute infections, cohort, and a subgroup of knee joints after 180 days.ConclusionsSAT after 12 weeks of antibiotic treatment for acute PJI managed with DAIR does not appear to improve patient outcomes.
Postoperative Urinary Incontinence in Diabetic Patients Undergoing Pelvic Reconstructive Surgery
Siddique, Moiuri, Ringel, Nancy E., Winter, K. Lauren de, Marczak, Tara, Kisby, Cassandra, Rutledge, Emily, Soriano, Alex, Samimi, Parisa, Schroeder, Michelle, Handler, Stephanie, Chou, Jiling, Gutman, Robert E., Kisby, Cassandra K. , Siddique, Moiuri, Ringel, Nancy E., Winter, K. Lauren de, Marczak, Tara, Rutledge, Emily, Soriano, Alex, Samimi, Parisa, Schroeder, Michelle, Handler, Stephanie, Chou, Jiling, Gutman, Robert E.

Mayo Clinic

Female Pelvic Medicine & Reconstructive Surgery | February 3, 2022 | Volume: 28 | Issue: 6 | Pages: 372-378

10.1097/spv.0000000000001137 | PMID 35113049 Get It

Importance Diabetes is an independent risk factor for urinary incontinence, and its impact on rates of postoperative incontinence after pelvic reconstructive surgery remains unexplored. Objective The aim of the study was to compare the incidence of postoperative stress urinary incontinence (SUI), urgency urinary incontinence (UUI), and mixed urinary incontinence in patients with diabetes mellitus undergoing surgery for pelvic organ prolapse (POP) with or without SUI surgery. Study Design This is a secondary analysis of a multicenter retrospective cohort study involving 10 diverse medical centers that identified a cohort of women with diabetes who had prolapse and/or anti-incontinence surgery. We compared rates of postoperative urinary incontinence among patients who had surgery for prolapse and incontinence versus surgery for prolapse only. Results Three hundred five patients had surgery for prolapse and incontinence, 330 had surgery for prolapse only, and 189 had anti-incontinence surgery only. De novo UUI was higher among those who underwent surgery for POP and SUI compared with surgery for POP alone (26.4% vs 14.1%, P < 0.01). Rates of persistent SUI (21% vs 4.9%, P < 0.01) and mixed urinary incontinence (15.9% vs 2.7%, P < 0.01) were higher for those who underwent prolapse surgery alone versus prolapse and an incontinence procedure. No differences were seen in hemoglobin A 1C levels between those who did and did not report postoperative UI. Conclusions We found that postoperative de novo UUI rates were high among patients with diabetes after pelvic reconstructive surgery, with the incidence being significantly higher for those who had surgery for prolapse and incontinence compared with surgery for prolapse only.